Literature DB >> 17498799

Anabolic effects of bisphosphonates on peri-implant bone stock.

Fabian von Knoch1, Christina Eckhardt, Claude I Alabre, Erich Schneider, Harry E Rubash, Arun S Shanbhag.   

Abstract

The long-term durability of total joint replacements is critically dependent on adequate peri-implant bone stock, which can be compromised by wear debris-mediated osteolysis. This study investigated the effects of bisphosphonates on enhancing peri-implant bone in the presence of clinically relevant ultra-high molecular weight polyethylene (UHMWPE) wear debris. Fiber-mesh coated titanium-alloy plugs were implanted bilaterally in the femoral condyles of 36 New Zealand white rabbits. Implants in the left femora were covered with submicron UHMWPE particles during surgery. Rabbits were administered either no drug, subcutaneous alendronate weekly (1.0mg/kg/week) or a single dose of intravenous zoledronate (0.015mg/kg). A total of 6/12 rabbits in each group were sacrificed at 6 weeks and the remainder at 12 weeks postoperatively. Peri-implant bone stock was analyzed radiographically and histomorphometrically. Radiographically, both bisphosphonates significantly increased periprosthetic cortical thickness at 6 weeks (p<0.0001; alendronate: +18%; zoledronate: +11%) and at 12 weeks (p=0.001; alendronate: +17%; zoledronate:+19%). Histomorphometrically, alendronate and zoledronate raised peri-implant bone volume (BV/TV) up to 2-fold after 6 weeks without added wear debris and more than 3-fold when wear debris was present. Furthermore a 6-week bisphosphonate treatment increased osteoid thickness in the absence of wear debris (alendronate: +132%, p=0.007; zoledronate: +67%, p=0.51) and in the presence of wear debris (alendronate: +134%, p=0.023; zoledronate: +138%, p=0.016). In summary, alendronate and zoledronate treatment increased periprosthetic bone stock in a rabbit femoral model, particularly in the presence of UHMWPE wear debris. These new findings suggest that bisphosphonates may more than compensate for the well-documented negative effects of wear debris on peri-implant bone stock. The combined antiresorptive and osteoanabolic effects of bisphosphonates on periprosthetic bone stock may have an important role for critically improving the biological fixation and ultimate durability of total joint arthroplasty.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498799     DOI: 10.1016/j.biomaterials.2007.04.024

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  12 in total

1.  Topical bisphosphonate augments fixation of bone-grafted hydroxyapatite coated implants, BMP-2 causes resorption-based decrease in bone.

Authors:  Jorgen Baas; Marianne Vestermark; Thomas Jensen; Joan Bechtold; Kjeld Soballe; Thomas Jakobsen
Journal:  Bone       Date:  2017-01-07       Impact factor: 4.398

2.  Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells.

Authors:  Jun Zhang; Jaesuh Park; Jung-Woo Lee; Yong-Dae Kwon; Eun-Cheol Kim
Journal:  Clin Oral Investig       Date:  2017-11-30       Impact factor: 3.573

3.  Intermittent PTH administration and mechanical loading are anabolic for periprosthetic cancellous bone.

Authors:  Matthew J Grosso; Hayden-William Courtland; Xu Yang; James P Sutherland; Kirsten Stoner; Joseph Nguyen; Anna Fahlgren; F Patrick Ross; Marjolein C H van der Meulen; Mathias P Bostrom
Journal:  J Orthop Res       Date:  2014-11-18       Impact factor: 3.494

4.  Pharmacological agents and bone healing.

Authors:  Umberto Tarantino; Irene Cerocchi; Monica Celi; Alessandro Scialdoni; Luca Saturnino; Elena Gasbarra
Journal:  Clin Cases Miner Bone Metab       Date:  2009-05

5.  Arthrotomy-based preclinical models of particle-induced osteolysis: A systematic review.

Authors:  Meghan M Moran; Brittany M Wilson; Ryan D Ross; Amarjit S Virdi; Dale Rick Sumner
Journal:  J Orthop Res       Date:  2017-06-28       Impact factor: 3.494

6.  Osteotropic beta-cyclodextrin for local bone regeneration.

Authors:  Xin-Ming Liu; Andrew T Wiswall; John E Rutledge; Mohammed P Akhter; Diane M Cullen; Richard A Reinhardt; Dong Wang
Journal:  Biomaterials       Date:  2008-01-15       Impact factor: 12.479

7.  Early changes in serum osteocalcin and body weight are predictive of implant fixation in a rat model of implant loosening.

Authors:  Brittany M Wilson; Meghan M Moran; Matthew J Meagher; Ryan D Ross; Maleeha Mashiatulla; Amarjit S Virdi; Dale R Sumner
Journal:  J Orthop Res       Date:  2019-12-25       Impact factor: 3.494

8.  Preclinical evaluation of zoledronate to maintain bone allograft and improve implant fixation in revision joint replacement.

Authors:  Mette Sørensen; Jeppe Barckman; Joan E Bechtold; Kjeld Søballe; Jørgen Baas
Journal:  J Bone Joint Surg Am       Date:  2013-10-16       Impact factor: 5.284

9.  Peri-implant and systemic effects of high-/low-affinity bisphosphonate-hydroxyapatite composite coatings in a rabbit model with peri-implant high bone turnover.

Authors:  Shun Niu; Xiaorui Cao; Yan Zhang; Qingsheng Zhu; Jinyu Zhu; Ping Zhen
Journal:  BMC Musculoskelet Disord       Date:  2012-06-11       Impact factor: 2.362

10.  Peri-implant Atypical Fractures Associated with Bisphosphonates: Should this Clinical Entity be Included in the Definition of Atypical Femoral Fracture? Case Report.

Authors:  Nuno Duarte Simões; Zico Gonçalves; João Moreno; Frederico Paiva; Serafim Pinho; Miguel Varzielas
Journal:  J Orthop Case Rep       Date:  2018 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.